Trading Report: The Stericycle Inc. (NASDAQ:SRCL) Receives Consensus Recommendation of “Hold” from Analysts

The Stericycle Inc. (NASDAQ:SRCL) Receives Consensus Recommendation of “Hold” from Analysts

Stericycle Inc. (NASDAQ:SRCL) has earned an average recommendation of “Hold” from the eighteen brokerages that are currently covering the firm. Three analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $97.85.

SRCL has been the topic of a number of analyst reports. Jefferies Group restated a “buy” rating and set a $112.50 target price (down from $125.00) on shares of Stericycle in a research report on Wednesday, September 7th. Zacks Investment Research upgraded Stericycle from a “hold” rating to a “buy” rating and set a $117.00 target price on the stock in a research report on Monday, July 11th. Wellington Shields cut Stericycle from an “accumulate” rating to a “hold” rating in a research report on Friday, July 29th. Finally, Macquarie initiated coverage on Stericycle in a research report on Thursday, August 25th. They set a “neutral” rating and a $96.00 target price on the stock.

In related news, EVP John P. Schetz sold 1,398 shares of Stericycle stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $81.85, for a total value of $114,426.30. Following the completion of the sale, the executive vice president now owns 1,088 shares in the company, valued at approximately $89,052.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rodney F. Dammeyer sold 10,188 shares of Stericycle stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $85.50, for a total transaction of $871,074.00. Following the completion of the sale, the director now owns 10,188 shares of the company’s stock, valued at approximately $871,074. The disclosure for this sale can be found here. Insiders own 3.30% of the company’s stock.

A number of hedge funds have recently bought and sold shares of SRCL. Vanguard Group Inc. increased its stake in Stericycle by 1.8% in the second quarter. Vanguard Group Inc. now owns 7,471,494 shares of the company’s stock valued at $777,932,000 after buying an additional 135,168 shares during the period. State Street Corp increased its stake in Stericycle by 0.5% in the first quarter. State Street Corp now owns 3,593,337 shares of the company’s stock valued at $453,442,000 after buying an additional 19,317 shares during the period. Baillie Gifford & Co. increased its stake in Stericycle by 77.2% in the second quarter. Baillie Gifford & Co. now owns 2,940,515 shares of the company’s stock valued at $306,166,000 after buying an additional 1,281,519 shares during the period. Jana Partners LLC bought a new stake in Stericycle during the first quarter valued at $305,997,000. Finally, BlackRock Institutional Trust Company N.A. increased its stake in Stericycle by 0.8% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,289,722 shares of the company’s stock valued at $288,940,000 after buying an additional 19,063 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Shares of Stericycle (NASDAQ:SRCL) traded down 0.98% during midday trading on Wednesday, reaching $76.58. The company’s stock had a trading volume of 513,194 shares. The company has a 50 day moving average price of $82.36 and a 200-day moving average price of $99.90. Stericycle has a 52 week low of $76.58 and a 52 week high of $151.57. The stock has a market capitalization of $6.51 billion, a PE ratio of 26.96 and a beta of 0.20.

Stericycle (NASDAQ:SRCL) last posted its earnings results on Thursday, July 28th. The company reported $1.18 EPS for the quarter, meeting the Zacks’ consensus estimate of $1.18. Stericycle had a return on equity of 14.84% and a net margin of 7.22%. The firm had revenue of $891.60 million for the quarter, compared to analysts’ expectations of $910.29 million. During the same period last year, the firm earned $1.14 EPS. The company’s quarterly revenue was up 24.6% on a year-over-year basis. On average, equities research analysts expect that Stericycle will post $4.67 EPS for the current year.

Related posts

Leave a Comment